DISCOVER SYLENTIS
Media

If you need to contact our communication department, please do it by contacting:

  • Lara Vadillo Muñoz
  • Miriam Collados Gordo
  • Pharma Mar Communication Dept.
  • Phone: +34 91 846 6000

Press releases

No posts found.

Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics

CAMBRIDGE, Mass. & MADRID–(BUSINESS WIRE)–Nov. 16, 2011— Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio-pharmaceutical company devoted to the research and development of new therapies based on RNAi, announced today that Alnylam has granted Sylentis a non-exclusive option for a new target-specific

Zeltia announces that subsidiary Sylentis has commenced Phase II clinical trials with its compound SYL1001 for treating eye discomfort associated with dry eye syndrome

SYL1001 is a compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye.   Madrid, 27 February

Sylentis presents new results on its ophthalmological compounds at ARVO 2018

The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies. The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be

Sylentis presented new results for the treatment of age associated macular degeneration

Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization .   Madrid, 4th of May, 2018. Within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), that has

Zeltia announces that subsidiary Sylentis has attained the primary endpoint of the Phase IIa clinical trial with its compound SYL040012.

SYL040012 is a novel compound arising from Sylentis’s research in ophthalmological disorders. It is indicated for treating ocular hypertension associated with glaucoma. SYL040012 is a chemical entity under the heading of interference RNA (RNAi). Sylentis is one of only five companies in the world with RNAi-based products undergoing clinical trials.

Sylentis participates in the 7th Spanish Conference on Glaucoma (SEG)

Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an oral communication entitled “Phase I Trial with SYL040012: New RNAi-based treatment for glaucoma”
error: Content is protected !!